Product News and Recalls

FDA considers stronger warning for diabetes drug

A story in the New York Times concerns efforts by federal regulators to develop a stronger label for the diabetes drug Byetta, manufactured by Eli Lilly, following more reports of deadly pancreatitis.

The U.S. Food and Drug Administration reported an additional six cases of pancreatitis. Two of the patients died and four were recovering.

An earlier FDA alert cited about 30 reports of Byetta patients developing a dangerous form of pancreatitis, which can cause nausea, abdominal pain and potentially deadly complications including development of pancreatic cancer.

Studies have also linked Byetta to an increased risk of thyroid cancer.

Byetta isn’t the only relatively new diabetes drug to carry that health risk. Januvia, made by Merck, has also been linked to an increased risk of pancreatitis and pancreatic cancer.

And previous studies have said that both drugs are no more effective than cheaper medications that were already on the market.

You should consult with a doctor if you have any ongoing symptoms or health concerns, and before making any changes in medication. You should also consult with a Lopez McHugh attorney if you or a loved one was diagnosed with pancreatic cancer after taking Januvia or Byetta.

See the story here: